Pharma among top-paid Indian execs; Teva gets FDA nod for one-dose Plan B;

> Pharma execs are among the highest paid in India, with three of the seven highest-paid executives hailing from Ranbaxy Laboratories, Dr Reddy's Labs and Piramal Healthcare. Report

> Teva Pharmaceutical industries won FDA approval for a one-dose form of the emergency contraceptive Plan B. Report

> Danish drugmaker Novo Nordisk is facing accusations by Swedish authorities that it treated hospital staff to an all-expenses-paid conference trip to South Africa, which if proven could lead to bribery charges. Report

> Par Pharmaceutical got the tentative FDA nod for its version of once-daily Tramadol, but patent disputes remain between Par, Purdue Pharma and Biovail, which make branded forms of the drug. Report

> Medtronic recalled specific lots of its Paradigm Quick Set infusion sets used with Minimed Paradign insulin pumps because they may not work properly. Report

> Sanofi-Aventis has recalled three cough mixtures for babies and children in France after traces of a toxic substance were discovered in a bottle, the French health authority said. Report

> Elan plans to delist from the London Stock Exchange due to low volumes but retain its primary Dublin listing and a presence on the New York Stock Exchange. Report

And Finally... Omega-3 fatty acid supplements did nothing to slow memory declines in people with mild to moderate Alzheimer's, but a study in healthy people with slight memory complaints did show promise. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.